

Mood disorders, sleep and circadian rhythms

Venkatramanujan Srinivasan¹
 Domenico De Berardis^{2,3}
 Michele Fornaro⁴
 Francisco López-Muñoz^{5,6,7}
 Timo Partonen⁸
 Rahimah Zakaria⁹

¹ Sri Sathya Sai Medical Educational and Research Foundation, International Medical Sciences Research Study Center "Prasanthi Nilayam", Tamilnadu, India

² NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4, Teramo, Italy

³ Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. D'Annunzio", Chieti, Italy

⁴ Department of Education Science, University of Catania, Catania, Italy

⁵ Faculty of Health Sciences, Camilo José Cela University, Madrid, Spain

⁶ Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health Sciences, University of Alcalá, Madrid, Spain

⁷ "Hospital 12 de Octubre" Research Institute, Madrid, Spain

⁸ Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland

⁹ Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia

Address for correspondence:

Venkatramanujan Srinivasan
 Research Director and Founder Chairman
 Sri Sathya Sai Medical Educational and Research Foundation
 International Medical Sciences Research Study Center
 "Prasanthi Nilayam", 40-Kovai Thirunagar, Goldwins,
 Kovai Coimbatore-641014, Tamilnadu, India
 E-mail: sainivasan@yahoo.com;
 sainivasan7@gmail.com

Abstract

Sleep disturbances and disruptions of circadian rhythms are underlying factors in most mood disorders like major depressive disorder (MDD) and

bipolar disorder (BD), and their seasonal pattern or seasonal affective disorder (SAD). Decreases in sleep efficiency, total sleep time and sleep quality have all been documented in MDD. In addition to this, depressed patients of all these three categories (MDD, BD, SAD) exhibit profound disturbances in circadian rhythms including the sleep-wake rhythm. Circadian clock dysregulation has been suggested to be due abnormal circadian rhythmicity of gene expression. In particular, *CRY1* and *CRY2* polymorphisms have been shown to be associated with MDD. Similarly, variations in *CRY2*, *PER2*, *ARNTL* and *NPAS2* are associated with SAD. An antidepressant that benefits sleep quality and resynchronize disrupted circadian rhythms will be most useful in treating mood disorders. In this context, the newly introduced melatonergic antidepressant agomelatine with MT₁ and MT₂ agonistic properties with 5-HT_{2C} antagonism has been documented to be beneficial, as it improves sleep, resynchronizes the disrupted circadian rhythms, and elevates mood. This drug also manifests with fewer adverse effects and is emerging as an effective antidepressant.

KEY WORDS: insomnia, sleep, clock genes, circadian rhythms, mood disorders, agomelatine.

Introduction

The clinical picture of mood disorders such as major depressive disorder (MDD) and bipolar disorder (BD) and their form with a seasonal pattern known as seasonal affective disorder (SAD) are dominated by pathological mood and psychomotor disturbances. The cluster of signs and symptoms seen in these disorders is sustained over a period of weeks to months, and they recur often in a period or cyclical fashion (1). As mood disorders happen to be cyclical also, disturbances in circadian rhythms have been implicated in these disorders (2). By definition, circadian rhythms are endogenous and are of "self-sustaining" in nature and will generate their rhythm and persist in the absence of any external input (3). Lesion experiments conducted in hypothalamic tissue have shown that the suprachiasmatic nucleus (SCN) of the hypothalamus acts as the major circadian pacemaker (4), and this master clock has been located in the SCN of humans as well (5). Numerous studies conducted on

depressive patients have shown that functioning of the circadian time keeping system is markedly affected in patients with BD (6-8).

Malfunctioning of the circadian time keeping system is said to be the reason for marked disturbances in the timing and distribution of rapid eye movement (REM) and non-rapid eye movement (NREM) sleep stages seen in patients with MDD, and these are documented as “primary characteristics” of MDD (9). Both epidemiological and electroencephalographic studies implicate “sleep disturbances” as a frequent underlying factor for mood disorders (10). Polysomnographic studies on patients with MDD or BD have found objective findings of sleep disturbances like difficulty in falling asleep, staying asleep, early morning awakenings (11). In addition, decreases in sleep efficiency (SE) and slow-wave sleep (SWS), and increases in sleep onset latency (SOL) and nocturnal awakenings have all been reported in patients with MDD (12). REM sleep abnormalities are considered as specific symptoms of MDD (13), although similar findings characterize patients with narcolepsy. Changes in the timing of the NREM-sleep-to-REM-sleep cycle within the night-time sleep in patients with depressive disorders are interpreted as a consequence of disorganized pathways regulating sleep-wakefulness cycle (7, 14).

As the circadian system, or the SCN, is involved in timing of the sleep propensity and wakefulness and consolidation of these two states (15), the SCN is considered as significant in regulating sleep-wake rhythm (16, 17). As neurons of the SCN express high concentration of both MT_1 and MT_2 melatonin receptors and melatonin acts on these receptors to alter the neuronal firing rate (18), or phase shift the neuronal firing rates in SCN (19), the hormone has important role in the regulation of both sleep-wakefulness cycle and circadian rhythms. Desynchronization of these two is considered as one of the key triggers for development of depressive disorders (19). Existence of disturbed sleep-wake cycles coupled with abnormalities of circadian rhythms, sleep disturbances, the cyclical nature of depressive disorders, and the diurnal variations in its symptomatology all implicate dysfunction of the circadian time keeping system as the major precipitating factor for depressive illness (20).

Sleep abnormalities in mood disorders

Sleep disturbances constitute one of the core features of depressive symptomatology as evidenced from the fact that more than 80% of depressed patients suffer from poor quality of sleep (21). Whether sleep disturbances in depression are “trait-like” feature, it remains as a controversial issue (22). In the early studies, it was demonstrated that changes in sleep architecture often preceded changes in clinical state and even predicted the relapse (23). Indeed, sleep has been included as one of the diagnostic criteria for MDD (24). Patients with depressive disorders experience all ma-

nor symptoms of insomnia including (a) difficulty in falling asleep, (b) difficulty in staying asleep, and (c) early morning awakenings (11). Sleep studies of slow-wave activity (SWA) in patients with MDD reveal that δ wave counts decreased as compared with sleep architecture of normal controls. Both fast-frequency β activity and elevated α activity have been noted in sleep recordings from depressive patients (9).

The temporal distribution of REM sleep is altered in patients with MDD. Decreased REM onset latency, that is the period from the onset of sleep to the appearance of first REM period, is the most common feature observed in MDD (13, 25, 26). It is suggested that reductions in NREM sleep, especially SWS, is the cause for reductions in REM sleep latency (27). A correlation between the reduced SWS and the abnormal temporal distribution associates with the increased severity of depressive symptoms and the increased risk of suicide (9). Many of the current antidepressants produce REM sleep suppression with the increase in REM onset latency prior to ameliorating the symptoms of depression (12).

It has been suggested that an ideal antidepressant should shorten the sleep latency, decrease the number of awakenings after sleep onset and increase the level of alertness during daytime (28), showing thereby the importance of “sleep disturbances in the pathogenesis of depressive disorders”. But, most of the conventional antidepressants that are in clinical use today act by elevating the daytime mood of depressed patients by activating the brain with rather non-specific mechanisms and persistence of this effect in the night will result only at the expense of sleep quality (29).

The status of sleep abnormalities as a diagnostic test for differentiating MDD from other psychiatric disorders was made in one meta-analysis and literature review. Using 31 publications the authors concluded that sleep studies for the detection of MDD appear replicable with a moderate effect size, and that additional studies are required for defining sensitivity and specificity (30). In a study on patients with schizophrenia and those with MDD, it was found that REM latency and REM sleep parameters had a significant relationship to clinical symptoms in MDD as assessed with the HDRS (Hamilton Depression Rating Scale) scores. Moreover, patients with MDD also differed from healthy controls in SOL, the number of awakenings after sleep onset, SWS, REM latency, and NREM sleep stage 1 (31, 32). Abnormalities in REM density and NREM sleep have been suggested to be potential biomarkers that persist even beyond remission in patients with MDD (33). Although unipolar and bipolar types of depression can be clearly distinguished, no significant differences are observed between these two groups in terms of nocturnal sleep patterns (34-36). Polysomnographic studies on patients with bipolar disorder with either depression or mania have shown that shortened REMOL and disturbed sleep continuity occur during manic episodes (37). Bunney and his associates have found that patients suffering from bipolar depressive disorder ex-

hibited marked reductions in sleep during the night before they switched from depression to mania (38) and this finding were confirmed in other study also (39). These studies were taken as evidences to propose that bipolar disorder symptoms are the result of internal desynchronization of circadian rhythms (40).

Circadian rhythm disturbances in mood disorders

Circadian clock malfunctioning has suggested to be a contributory factor for mood disorders such as MDD, BD and SAD (40). Mood and circadian rhythms have a reciprocal relationship and share common features in neurobiology, clinical presentation and treatment methods. An interrelation between sleep, circadian rhythms and mood is illustrated in Figure 1. It is modified from the model presented by Foley et al. (41). Disruptions of the circadian timekeeping system is said to result in neurobiological dysfunction due to changes in melatonergic system and those in the circadian clock functions, ultimately manifesting as a depressive episode and in subsequent as illness (40). The early evidence linking mood regulation and circadian rhythms was based on the phase-shift hypothesis, according to which mood disturbances arise from either a phase advance or a phase delay of the master circadian pacemaker with the rhythms of melatonin, cortisol, core body temperature, REM sleep, other circadian rhythms, and with the sleep-wake cycle (42). Kripke and his co-workers proposed in 1983 (43) that depression is due to the internal desynchronization of circadian oscillators, with a strong oscillator being linked to phase advances. Phase advances of core body temperature and REM sleep cycles in relation to the rest-activity cycles were reported in both unipolar and bipolar depressed patients (44). Similarly, a phase advance of (3 to 6 hours for) the peak of 3-methoxy-4-hydroxyphenylglycol excretion was reported in both manic and depressed patients (45). Abnormalities in the timing and distribution of REM and NREM sleep stages are suggested as primary characteristics of MDD (9). Hence, the proper study and understanding of the mechanisms involved in sleep and circadian rhythms disturbances will be

helpful for explaining the pathophysiology that underlies mood disorders (46).

Some studies demonstrate that suppression of REM sleep results in improvement of mood and have resorted into sleep deprivation (wake) therapy. However, the therapeutic effects of sleep deprivation therapy are influenced by the patient's characteristics and the diurnal variation in mood that contribute to the prognosis after sleep deprivation therapy (47). The relationship between mood adjustment and the circadian clock systems that regulate "diurnal preference" should also be considered while treating the patient. In this context, it has been found that the evening-type of preference to the daily activities increases the susceptibility for development of mood disorders (48, 49). Hence, the individual genetic effects that control the molecular mechanisms of circadian clocks are involved in mood disorders, and the assessment of these effects as well as response to treatment are important and need attention while treating patients with mood disorders.

A bidirectional relationship between regulation of daytime affect and night-time sleep exists, and disturbances during the day affect the night-time sleep and circadian functions (50). Most of the core symptoms of MDD exhibit circadian rhythmicity and are governed by the molecular clocks present in the SCN. The diurnal mood variation has its lowest point in the morning hours in most of the patients with MDD (42, 51). A poor coupling of the circadian oscillators to the external or the internal rhythms has been demonstrated in certain mood disorders.

Circadian clock genes and mood disorders

Polymorphisms in the core oscillator genes *CRY2*, *PER2*, *ARNTL* and *NPAS2* have been found to associate with SAD (52, 53). Sequence variations in these genes that form the functional unit at the core circadian clock have been shown to predispose to SAD, in specific to winter depression (52). Moreover, a detailed pattern of circadian gene expression was carried out with high quality post-mortem human brain samples obtained from six cortical and limbic regions (dorsolateral prefrontal cortex, anterior cingulate cortex, hippocampus, amygdala, nucleus accumbens, cerebellum) derived from 55 controls with no history of psychiatric or neurological illness, and from 34 patients with MDD (54). Among the top-ranked rhythmic genes that were covered in this study were the known clock genes *ARNTL*, *PER2*, *PER3*, *NR1D*, *DBP*, *BHLHE40* and *BHLHE41*. Findings of this study revealed the cyclical patterns for most of the known circadian genes and offered empirical evidence for molecular dysregulation of circadian rhythms across six brain regions of clinically depressed patients. Patients with MDD exhibited an abnormal phasing of circadian gene expression and disrupted phase relationships between circadian genes, which account for the disruption of regulation of a range of neural processes and behaviour that are manifested as MDD (54).




Figure 1 - Basic relationship of circadian rhythm, sleep and mood regulation.

Results of this study could pave the way for identification of novel biomarkers and treatment targets for mood disorders (54).

In studies carried out on *CRY2* gene expression in depression, the effect of total sleep deprivation on the circadian oscillation of *CRY2* mRNA in human peripheral blood mononuclear cells was assessed, and it was observed that one-night total sleep deprivation led to an increase in *CRY2* mRNA levels in controls whereas in depressed patients with BD there was a decrease in *CRY2* mRNA levels (55). Further in this study, *CRY2* genetic variants were found to be significantly associated with winter depression or SAD (55). A recent study carried out on Chinese population involving 105 subjects with MDD and 485 controls reveals that MDD patients have significantly higher frequencies of C-allele and CC-genotype in *CRY1* rs2287161 and those of T-allele and TT-genotype in *TEF* rs738499 than controls (56). *CRY2* is a circadian gene that participates in regulation of the evening oscillator and its link to vulnerability for depression has been reported earlier in depressed bipolar patients (57). However, it needs to be pointed out that the Psychiatric Genomics Consortia for schizophrenia, BD and MDD found no evidence for association of genes linked to control of the circadian rhythms and suggested that genes encoding components of molecular clock are not good candidates for harboring common variants that increase the risk to BD, schizophrenia or MDD (58). However, the genome-wide association studies that combine samples from different populations may not cover all the circadian genes and their variants and might thus have lost the relevant information.

The current understanding is that proteins encoded by the core circadian clock genes *ARNTL*, *ARNTL2*, *CLOCK* and *NPAS2* form heterodimers and bind to sites, or “boxes”, to initiate the transcription of their tar-

get genes among which are the core circadian clock genes *CRY1*, *CRY2*, *PER1* and *PER2*. In turn, proteins encoded by these latter genes form heterodimers and act as repressors of the transcription-translation feedback loops of the circadian clocks. Sleep-related chronotherapies such sleep deprivations and sleep phase advances are effective in resetting the abnormal clock gene machinery and thereby correcting the abnormal circadian rhythms in terms of the phase, period and amplitude. This fact and the finding that these chronotherapies lead to improvement in mood suggest that “altered clock gene machinery” is likely to represent a core pathophysiological defect in a subset of patients with mood disorders (59).

Certain polymorphisms of *ARNTL* are said to associate with the predisposition to BD (60). Other circadian clock genes with a polymorphism reported to associate with BD include *CLOCK* (59), *NR1D1* and *Per3* (61-64). Meta-analysis of integrating data obtained from genome-wide association studies, as well as human and animal model studies, point out that other circadian genes like *RORA* and *RORB* are also associated with BD (65). Genetic variations in *ARNTL* are in addition found to associate with SAD (66). Activation of circadian gene transcription varies with the time of the day also. In day-active animals, *PER1* and *PER2* get activated in the morning hours, while *CRY1* and *CRY2* get activated in the evening hours (67). Both the dawn and dusk components, *PER2* and *CRY2* genetic variants respectively, are associated with SAD in particular (6, 57). A schematic diagram of polymorphisms of clock genes and mood disorders is presented in Figure 2.

There may be hundreds of genes in the human brain that are likely to be involved in the daily rhythmic events including the sleep-wake cycle. Daily rhythms in these genes are dysregulated in patients with mood




Figure 2 - Polymorphisms of clock genes and mood disorders.

disorders, suggesting thereby that mood disorders are due to dysregulation of circadian functions. This has been sufficiently substantiated by the abnormal rhythms in core body temperature, cortisol, melatonin, 3-methoxy-4-hydroxyphenylglycol, REM sleep latency, decreases in total sleep time and sleep efficiency, as has been discussed in the earlier paragraphs.

Studies of the physiological and molecular mechanisms underlying disrupted circadian rhythms and dysregulated sleep-wake mechanisms will greatly help not only in understanding the pathophysiology of mood disorders, but also will help to treat these disorders more effectively. Insomnia occurs in nearly 60 to 80% of patients with MDD (68). Antidepressant drugs that are commonly prescribed for treatment of depression may actually worsen insomnia and thus impair and postpone the full clinical remission from the illness. Tricyclic antidepressants, selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors all cause not only REM sleep suppression, but also may thereby aggravate insomnia of depressed patients (69). A comprehensive program of therapy for depression should address not only its clinical and behavioural signs and symptoms, but should focus its attention on concomitant symptoms like sleep and circadian rhythm disturbances (46, 68).

Agomelatine use for mood disorders

As depressive disorders are linked to disturbances of circadian rhythms, an antidepressant that benefits sleep quality and resets the disturbed circadian rhythms will have a superior efficacy (69, 70). An ideal anti-depressant should decrease SOL, decrease the number of awakenings after sleep onset, increase sleep quality during the night, and improve alertness during the day (71). Close to such ideal drug is the newly introduced melatonergic antidepressant agomelatine (Servier), an MT₁ and MT₂ melatonergic receptor agonist with 5-HT_{2C} antagonistic properties. This drug got its approval in November 2008 by the European Medicines Agency. A number of clinical trials involving multicenter and multinational studies has documented the clinical efficacy of agomelatine in MDD and found it having the efficacy superior over placebo in terms of response during the acute phase of treatment. The efficacy of agomelatine over sertraline, fluoxetine and escitalopram in MDD has been well documented. Agomelatine's treatment efficacy based on HDRS, CGI and Montgomery-Åsberg Depression Rating Scale (MADRS) have all been reviewed and its efficacy is equal to any other antidepressant (72-74).

Unlike other antidepressants agomelatine improves sleep continuity and sleep quality, increases sleep efficiency and the total amount of SWS (75). It also improves early NREM and REM sleep (76). A greater reduction in SOL during the night with a reduced daytime sleepiness was seen in agomelatine-treated depressed patients as compared with patients treated with escitalopram.

Agomelatine normalizes NREM sleep in depressed patients (77). Since changes in NREM sleep precede the clinical improvement, as assessed with the HDRS, it has been suggested that agomelatine's antidepressant effect is mediated through its ability to normalize sleep architecture (78). EEG analysis of the effects of agomelatine on sleep in patients with MDD shows that agomelatine (25 mg per day for 6 weeks) increases sleep efficiency with a decrease in awakenings, starting from day 7 onwards. Both SWS duration and percentage of time spent in SWS (sleep stages 3 and 4) increase significantly (78). As agomelatine did not influence REM latency or the amount of REM sleep, its antidepressant effect has been attributed to its action on correcting the abnormalities of the homeostatic system of sleep regulation (78).

Agomelatine's potential superiority over other antidepressants of the 5-HT_{2C} antagonists has been attributed to its effect of improving sleep at night and alertness during the day that is not seen with the use of other antidepressants. With agomelatine's combined mechanism of actions of preserving sleep quality at night-time and elevating mood during daytime, depressed patients experience a better quality of life (79). Agomelatine's sleep promoting melatonergic action counteracts its antihypnotic actions mediated through its 5-HT_{2C} antagonism. 5-HT_{2C} receptors are concentrated in the frontal cortex, amygdala, hippocampus and corticolimbic structures that all are involved in the regulation of mood and cognition (79).

As we have discussed in the earlier paragraphs, disruptions of circadian rhythms also correlate with the clinical severity of depression, a finding that is attributed to disturbances of sleep-wake cycle. As agomelatine is a specific agonist of MT₁ and MT₂ melatonergic receptors located in the SCN, it exerts its action by resetting the disturbed circadian rhythms including the sleep-wake rhythms seen in patients with MDD, and this action should be considered as an important component of its antidepressant effects. Agomelatine's chronobiotic effect was studied in healthy older men where this drug (50 mg per day) caused phase advances by 2 hours on average in core body temperature profiles and in the temporal organization of cortisol secretion (80). Phase delays of the circadian rhythms relative to the timing of the habitual sleep-wake cycle are an important contributing factor for the pathophysiology of SAD. Treatment with agomelatine (25 mg per day for 14 weeks) for acutely depressed patients with SAD by using *circascreen* (a self-rating scale for the assessment of sleep and circadian rhythm disturbances) demonstrated that the drug alleviated symptoms significantly from the second week of treatment onwards, and suggested that its hypnotic and resetting effects are important in the treatment of SAD. In a recent multicenter observational CHRONOS study conducted on 6,276 depressed patients agomelatine caused reduction in HAMD – score from a mean of 22.5 p6.9 at baseline to 4.7p4.7 at the end of 8 week treatment period. Improvements in sleep-wake cycle were confirmed in this study by the marked improvements in all three in-

somnia related HAMD -17 items (81). Rates of response and remission were high in both overall population and in the subgroup of severely depressed patients. As benefits of treatment observed in randomized studies do not always translate into clinical practice, the authors of the present study evaluated the antidepressant efficacy and tolerability of agomelatine in the naturalistic study and found agomelatine caused rapid onset of benefit across all HAMD-17 items showing agomelatine as highly effective in the treatment of depressive episodes in a “real world” clinical setting (81).

Conclusions

Disturbed sleep and disrupted circadian rhythms are two cardinal features seen in patients suffering from all three major types of mood disorders, including MDD, BD and SAD or winter depression. Sleep disturbance and depression have reciprocal relationships and influence each other. In MDD, sleep disturbances are a part of the diagnostic criteria. Besides exhibiting all major symptoms of insomnia like decreases in total sleep time and sleep efficiency, depressed patients also exhibit alteration in the temporal distribution of REM sleep. Polysomnographic studies on patients with MDD or BD yield objective findings of sleep disturbances, and these features are even used as “biologic markers” for identifying the specific type of mood disorders.

The task of a given antidepressant should be not only to improve the clinical and behavioural features, but also to improve the concomitant sleep disturbances. Hence, the effects of antidepressant on sleep should be given a main importance while prescribing a drug for treatment of depressive disorders. Second, as depression is linked to disturbances of circadian rhythms, an ideal antidepressant should reset the disrupted circadian rhythms in addition to correct the abnormalities of sleep stage dynamics. The currently used antidepressants while effective in producing a clinical remission also may exacerbate insomnia and may thus not be effective enough in tackling circadian and sleep-wake rhythm disturbances. In this context, the recently introduced melatonergic antidepressant agomelatine, with its dual mechanism of action on MT₁ and MT₂ melatonergic receptors in the SCN and other brain regions associated with sleep and circadian rhythm regulation, promotes sleep and resynchronize the disrupted circadian rhythms back to normal. These actions by themselves improve the clinical state of depressed patients having MDD, BD or SAD. In addition, agomelatine's action through 5-HT_{2C} antagonism in the prefrontal cortex, corticolimbic structures, hippocampus and amygdala, which are the key brain regions involved in mood regulation, relieves symptoms of depression and helps to achieve the clinical remission. All these events reinforce the hypothesis of direct involvement of melatonergic system in the aetiology of sleep and depressive disorders.

References

1. Kahn D. Mood disorders, in Text Book of Psychiatry. Edited by Cutler IG, Marcus ER, Philadelphia, WB Saunders Company, 1999, pp. 33-63.
2. Wehr TA, Sack D, Rosenthal N, Duncan W, Gillin JC. Circadian rhythm disturbances in manic depressive illness. Fed Proceedings 1983; 42:2809-2813.
3. Aschoff J. Circadian rhythms in man. Science 1965; 148:1427-1432.
4. Moore RY, Klein DC. Visual pathways and central neural control of a circadian rhythm in pineal serotonin-N-acetyl-transferase activity. Brain Res. 1974; 71:17-33.
5. Sadun AA, Schaechter JD, Smith LE. A retinohypothalamic pathway in man: light mediation of circadian rhythms. Brain Res. 1984; 302:371-377.
6. Bunney WE Jr, Murphy DL, Goodwin FK, Borge GF. The switch process from depression to mania. Relationship to drugs which alter brain amines. Lancet 1970; 1(7655):1022-1027.
7. Sitaram N, Gillin JC, Bunney WE Jr. The Switch process in manic-depressive illness. Circadian variation in time of switch in sleep and manic ratings before and after switch. Acta Psychiatrica Scand. 1978; 58:267-278.
8. Wehr T, Goodwin FK. Tricyclics modulate frequency of mood cycles. Chronobiologia 1979; 6:377-385.
9. Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand. 2007; 115 (suppl 433):104-115.
10. Peterson MJ, Bnca RM. Sleep in mood disorders. Psychiatr Clin North Am. 2006; 29:1009-1032.
11. Cajochen C, Brunner DP, Krauchi K, Graw P, Wirz-Justice A. EEG and subjective sleepiness during extended wakefulness in seasonal affective disorder: circadian and homeostatic influences. Biol Psychiatry 2000; 47:610-617.
12. Lam RW. Sleep disturbances and depression; a challenge for antidepressants. Int Clin Psychopharmacol. 2006; 21 (suppl 1):S25-S29.
13. Schulz H, Lund R, Cording C, Dirlich G. Bimodal distribution of REM sleep latencies in depression. Biol Psychiatry 1979; 14:595-600.
14. Duncan WC Jr, Pettigrew KD, Gillin JC. REM architecture changes in bipolar and unipolar depression. Am J Psychiatry 1979; 136:1424-1427.
15. Zee PC, Manthena P. The brain's master circadian clock. Implications and opportunities for therapy of sleep disorders. Sleep Med. 2007; 11:59-70.
16. Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: Evidence for opponent processes in sleep-wake regulation. J Neurosci. 1993; 13(3):1065-1079.
17. Kawato M, Fujita K, Suzuki R, Winfree AT. A three-oscillator model of the human circadian system controlling the core temperature rhythm and the sleep-wake cycle. J Theor Biol. 1982; 98:369-92.
18. Liu C, Weaver DR, JinX, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the supra chiasmatic circadian clock. Neuron 1997; 19:91-102.
19. Healy D. Rhythms and blue: neurochemical, neuropharmacological and neuropsychological implications of a hypothesis of circadian rhythm dysfunction in the affective disorders. Psychopharmacology 1987; 93:271-285.
20. Srinivasan V, Smits M, Spence, Lowe AD, Kaymov L, Pandi-Perumal SR, Parry B, Cardinali DP. Melatonin in mood disorders. World J Psychiatry 2006; 7(3):138-151.
21. Reynolds CF, Kupler D. Sleep in Depression, in Sleep disorders, diagnosis and treatment. Edited by Williams RZ, Karakan I, Moore CA. New York, John Wiley, 1988, pp. 147-164.

22. Berger M, Riemann D. REM sleep in Depression an overview, in Symposium Normal and abnormal REM sleep regulation. *J Sleep Res.* 1993; 2:211-223.
23. Kupfer DJ, Spiker DG, Coble PA, Neil JF, Ulrich R, Shaw DH. Sleep and Treatment prediction in endogenous depression. *Am J Psychiatry* 1981; 138:429-434.
24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 4th Edition (DSM-IV), Washington DC, American Psychiatric Press 1994.
25. Wehr TA, Wirz-Justice A, Goodwin FK, Duncan W, Gillin JC. Phase advance of the circadian sleep-wake cycle as an anti-depressant. *Science* 1979; 206:710-713.
26. Cartwright R, Baehr E, Kirkby J, Pandi-Perumal SR, Kabat J. REM sleep reduction, mood regulation and remission in untreated depression. *Psychiatr Res.* 2003; 121:159-167.
27. Lustberg L, Reynolds CF. Depression and insomnia: questions of cause and effect. *Sleep Med.* 2000; 6(suppl 2):253-262.
28. Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. *Eur Neuropsychopharmacol.* 2006; 16(suppl 5):S639-S643.
29. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin norepinephrine and dopamine levels in humans: a meta analysis of monoamine depletion studies. *Mol Psychiatry* 2007; 12:331-359.
30. Arfken CL, Joseph A, Sandhu GR, Roehrs T, Douglass AB, Boutros NN. The status of sleep abnormalities as a diagnostic test for major depressive disorder. *J Affect Disor.* 2014; 156:36-45.
31. Ilankovic A, Damjanovic A, Ilankovic V, Filipovic B, Jankovic S, Ilankovic N. Polysomnographic sleep patterns in depressive, schizophrenic and healthy subjects. *Psychiatria Danubina.* 2014; 26(1):20-26.
32. Ilankovic N, Marinokovic D, Bugarski D, Ignjtovic M. Models of exogenous endogenous sleep perturbation as diagnostic and therapeutic predictors in depression. *Methods Find Exp Clin Pharmacol.* 1986; 8:513-517.
33. Pillai V, Kalmbach DA, Ciesla JA. A meta-analysis of electroencephalographic sleep in depression: evidence for genetic biomarkers. *Biol Psychiatry.* 2011; 70:912-919.
34. Duncan WC Jr, Pettigrew KD, Gillin JC. REM architecture changes in bipolar and unipolar depression. *Am J Psychiat.* 1979; 136:1424-1427.
35. Lauer CJ, Wiegand M, Kreig JC. All-night electroencephalographic sleep and cranial computed tomography in depression. A Study of unipolar and bipolar patients. *Eur Arch Psychiat Clin Neuroscience.* 1992; 242:59-68.
36. Riemann D, Berger M, Voderholzer U. Sleep and depression - results from psycho biological studies. An overview. *Biol Psychol.* 2001; 57:67-103.
37. Hudson JI, Lipinski JF, Keck PE Jr, Aizley HG, Lukas SE, Rothschild AJ, Watermaux CM, Kupfer DJ. Polysomnographic characteristics of young manic patients. Comparison with unipolar depressed patients and normal control subjects. *Arch Gen Psychiat.* 1992; 49:378-383.
38. Bunney WE Jr, Murphy DL, Goodwin PK, Borge GF. The switch process from depression to mania; relationship to drugs which alter brain monoamines. *Lancet.* 1970; 1:1022-1027.
39. Sitaram N, Gillin JC, Bunney WE Jr. The switch process in manic-depressive illness. Circadian variation in time of switch and sleep and manic ratings before and after switch. *Acta-Psychiatr-Scand.* 1978; 58:267-278.
40. Costa IC, Carvalho HN, Fernandes L. Aging, circadian rhythms and depressive disorders: a review. *Am J Neurodegener Dis.* 2013; 2(4):228-246.
41. Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 National sleep Foundation, Sleep in America Survey. *J Psychosom Res.* 2004; 56:497-502.
42. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. *Hum Psychopharmacol.* 2008; 23:571-585.
43. Kripke DJ, Risch SC, Janowsky D. Bright white light alleviates depression. *Psychiat Res.* 1983; 10:105-112.
44. Wehr TA, Goodwin FK, Wirz-Justice A, Breitmaier J, Craig C. 48 hr sleep-wake cycles in manic-depressive illness: naturalistic observations and sleep deprivation experiments. *Arch Gen Psychiat.* 1982; 39:559-565.
45. Wehr TA, Muscettola G, Goodwin FK. Urinary 3-methoxy-4-hydroxyphenylglycol circadian rhythm. Early timing (phase-advance) in manic depressive compared with normal subjects. *Arch Gen Psychiat.* 1980; 37:257-263.
46. Srinivasan V, Pandi-Perumal SR, Trakht I, Spence DW, Harel-land R, Poegger B, Cardinali DP. Pathophysiology of Depression. Role of sleep and the melatonergic system. *Psychiat Res.* 2009; 165:201-214.
47. Bouhuys AL. Towards a model of mood responses to sleep deprivation in depressed patients. *Biol Psychiatry* 1991; 29:600-612.
48. Kitamura S, Hida A, Watanabe M, Enomoto M, Aritate-Okada S, Moriguchi Y, Kamei Y, Mishima K. Evening preference is related to the incidence of depressive states independent of sleep-wake conditions. *Chronobiol Int.* 2010; 27:1797-1812.
49. Merikanto I, Lahti T, Kronholm E, Peltonen M, Laatikainen T, Vartiainen E, Salomaa V, Partonen T. Evening types are prone to depression. *Chronobiol Int.* 2013; 30:719-725.
50. Luca A, Luca M, Calandra C. Sleep disorders and depression: brief review of the literature, case report and non-pharmacologic interventions for depression. *Clinical Interventions in Aging* 2013; 8:1033-1039.
51. Mendlewicz J. Circadian rhythm disturbances in Depression France: Wolters Kluwer Health 2008.
52. Partonen T, Treulein J, Alpmann A, Frank J, Johansson C, Depner M, Aron L, Rietschel M, Wellek S, et al. Three circadian clock genes *Per2*, *Arntl* and *Npas2* contribute to Winter Depression. *Ann Med.* 2007; 39(3):229-238.
53. Partonen T. Clock gene variants in mood and anxiety disorders. *J Neural Transm.* 2012; 119:1133-1145.
54. Li JZ, Bunney BG, Meng F, Hagenauer MH, Walsh DM, Vawter MP, Evans SJ, Choudry PV, Cartagena P, Barchas JD, Schatzberg AF, Jones EG, Myers RM, Watson Jr SJ, Bunney WE Jr. Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. *PNAS.* 2013; 110(24):9950-9955.
55. Lavebratt C, Sjöholm LK, Soronen P, Paunio T, Vawter M, Bunney WE Jr, Adolffson R, Forsell Y, Wu JC, Kelsoe JR, Partonen T, Schalling M. *CRY2* is associated with depression. *Plos One.* 2010; 5(2):e9407 doi:10.1371/journal.pone.0009407.
56. Hua P, Liu W, Chen D, Zhao Y, Chen L, Zhang N, Wang C, Guo S, Wang L, Xiao H, Kuo SH. *Cry1* and *Tef* gene polymorphisms are associated with major depressive disorder in the chinese population. *J Affect Disord.* 2014; 157:100-103.
57. Lavebratt C, Sjöholm LK, Partonen T, Schalling M, Forsell Y. *PER2* variation is associated with depression variability. *Am J Med Genet B Neuropsychiatr Gene.* 2010; 153B:570-581.
58. Byrne EM, Heath AC, Madden PA, Pergadia ML, Hickie IB, Montgomery GW, Martin NG, Wray NR. Testing the role of circadian genes in conferring risk of psychiatric disorders. *Am J Med Genet B Neuropsychiatr Genet.* 2014; 165(3):254-260.
59. Bunney BG, Bunney WE. Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms. *Biol Psychiatry.* 73(12):1164-1171.
60. Rybakowski JK, Dmitrzak-Weglarz M, Dembinska-Krajewska D, Hauser J, Akiskal KK. Polymorphism of circadian clock genes and temperamental dimensions of the *TEMPS-A* in bipolar disorder. *J Affect Disord.* 2014; 159:80-84.
61. Shi J, Wittke-Thompson JK, Badner JA, Hattori E, Potash JB, Willour VL, McMahon FJ, Gershon ES, Liu C. Clock genes

- may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. *Am J Med Genet Part B Neuropsychiatr Genet.* 2008; 147B:1047-1055.
62. Mansour HA, Wood J, Logue T, Chowdari KV, Dayal M, Kupfer DJ, Monk TH, Devlin B, Nimgaonkar VL. Association study of eight circadian genes with bipolar 1 disorder, schizoaffective disorder and schizophrenia. *Genes Brain Behav.* 2006; 5:150-157.
 63. Nievergelt CM, Kripke DF, Barren TB, Burg E, Remick RA, Sadvnick AD, McElroy SL, Keck PE Jr, Schork NJ, Kelsoe JR. Suggestive evidence for association of the circadian genes PERIOD3 and ARNTL with bipolar disorder. *Am J Med Genet, B Neuropsychiatr Genet.* 2006; 141:234-241.
 64. Kripke DF, Nievergelt CM, Joo EJ, Shekman T, Kelsoe JR. Circadian polymorphism associated with affective disorders. *J Circadian Rhythms.* 2009; 7:2.
 65. Le-Niculescu H, Patel SD, Bhat M, Kuczenski R, Faraone SV, Tsuang MT, McMahon FJ, Schork NJ, Nurnberger JI Jr, Niculescu AB 3rd. Convergent functional genomics of genome-wide association data for bipolar disorder comprehensive identification of candidate genes, pathways and mechanisms. *Am J Med Genet B Neuropsychiatr Genet.* 2009; 150B:155-181.
 66. Johansson C, Willeit M, Smedh C, Ekholm J, Paunio T, Kieseppä T, Lichtermann D, Praschak-Rieder N, Neumeister A, Nilsson LG, Kasper S, Peltonen L, Adolfsson R, Schalling M, Partonen T. Circadian Clock-related polymorphisms in seasonal affective disorder and their relevance to diurnal preference. *Neuropsychopharmacology.* 2003; 28:734-739.
 67. Lincoln GA, Anderson H, Hazlerigg D. Clock genes and long term regulation of prolactin secretion: evidence for a photoperiod/circannual timer in pars tuberalis. *J Neuroendocrinol.* 2003; 15:390-397.
 68. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP. Depression, sleep physiology and antidepressant drugs. *Depression Anxiety.* 2001; 14:19-28.
 69. Srinivasan V, Brzezinski A, Spence DW, Pandi-Perumal SR, Hardeland R, Brown GM, Cardinali DP. Sleep, mood disorders, and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment. *Psychiatria Fennica.* 2010; 41:168-187.
 70. Srinivasan V, Brzezinski A, Pandi-Perumal SR, Spence DW, Cardinali DP, Brown GM: Melatonin agonists in primary insomnia and insomnia of depression. Are they superior to sedative hypnotics? *Progr Neuropsychopharmacol Biol Psychiatry.* 2011; 35:913-923.
 71. Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. *Eur Neuropsychopharmacol.* 2006; 16(suppl 15):5639-5643.
 72. De Berardis D, di Lorio G, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di Giannantonio M. The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine. *CNS Neurol Disord Drug Targets.* 2011; 10:119-132.
 73. De Berardis D, Marini S, Fornaro M, Srinivasan V, Iasevoli F, Tomasetti C, Valchera A, Perna G, Quera-Salva MA, Martinotti G, di Giannantonio M. The Melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice. *Int J Mol Science.* 2013; 14(6):12458-12483.
 74. Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. *Expert Opin Invest Drugs.* 2012; 21:1503-1522.
 75. Martinotti G, Sepede G, Gambi F, Di lorio G, De Berardis D, Di Nicola M, Onofri M, Janiri L, Di Giannantonio M. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A Pilot Study. *J Clin Psychopharmacol.* 2012; 32:487-491.
 76. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. *J Clin Psychopharmacol.* 2008; 28:329-333.
 77. Lopes MC, Quera-Salva MA, Guilleminault C. Cycling alternating patterns in the NREM sleep of patients with major depressive disorder. *Sleep Med.* 2005; 6(suppl 2):87-88.
 78. Pjrek E, Winkler D, Konstantinids A, Willeit M, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. *Psychopharmacology (Berl)* 2007; 190:575-579.
 79. Millan MJ. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. *Pharmacol Ther.* 2006; 110:135-370.
 80. Leproult R, Van Onderberger A, L'hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. *Clin Endocrinol. (Oxf)* 2005; 63:298-304.
 81. Ivanov SV, Samushiya MA. Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study. *Neuropsychiatric Disease and Treatment.* 2014; 10:631-639.